Optimi Health To Supply MDMA For Therapist Experiential Training Program at Numinus, Supported by MAPS

The company was selected to manufacture and supply MDMA for the program set to take place later this year, pending clinical trial approval

VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes and in controlled patient markets, psychedelic substances such as GMP-grade 3,4-Methylenedioxymethamphetamine (“MDMA”) and natural psilocybin, along with natural health product formulations, is pleased to announce that it has been selected to manufacture and supply MDMA for a practitioner experiential clinical trial, sponsored by Numinus Wellness Inc. (“Numinus”), announced earlier today. This clinical trial will provide practitioners training to provide MDMA-assisted therapy with the opportunity to participate in experiential training – through a training partnership between Numinus and the Multidisciplinary Association for Psychedelic Studies (“MAPS”).

The clinical trial application has been submitted by Numinus through its wholly owned subsidiary Numinus Wellness Research Inc. If approved by Health Canada, the clinical trial would enable practitioners interested in MDMA-assisted therapy the ability to experience and observe MDMA sessions to further their understanding of psychedelic-assisted therapy and allow Numinus to test the safety and efficacy of MDMA in healthy subjects.

Optimi CEO, Bill Ciprick, says this latest supply partnership confirms the Company’s “all-in” approach to supporting therapists and being a preferred supplier of MDMA.

“Optimi is committed to supporting Numinus and MAPS as they prepare to meet this immediate need for therapist and practitioner training,” said Ciprick. “Therapists provided experiential training within the parameters of this partnership will be able to provide a greater standard of care to patients undergoing these treatments. We are excited to be part of the journey.”

Numinus Founder and CEO, Payton Nyquvest, added: "We are thrilled to announce this unique partnership with Optimi that opens the doors to a groundbreaking opportunity for psychedelic therapists worldwide,” said Nyquvest. “Along with MAPS, we are pioneering a new era of research and access to MDMA-assisted therapy, empowering therapists to unlock transformative healing journeys for their clients. This collaboration represents our unwavering commitment to expanding the frontiers of mental health, providing a safe and guided path towards profound healing and personal growth."

Optimi will answer questions during a live webinar after the MAPS Psychedelic Science 2023 conference. Details to follow.


Michael Kydd
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca


Optimi Health Corp. is an end-to-end Canadian-based drug researcher and formulator licensed by Health Canada to produce and supply psychedelic substances such as 3,4-Methylenedioxymethamphetamine (“MDMA”) and natural, GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA producer in North America.

Operational Strength:

  • Optimi is producing OPTI-MHCL in-house under its Health Canada issued Dealers Licence using Optimi’s scalable, proprietary production method.

  • Optimi is also manufacturing MDMA under GMP-compliant protocols, making additional MDMA product available for clinical research, drug development, and therapist training initiatives.

  • OPTI-MHCL was tested for purity on-site with a result of >99% which the Company is validating through a third-party laboratory.

  • Received a GMP Natural Health Product site licence by Health Canada.


This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐looking statements pertaining to activities proposed to be conducted under the Company’s approved Health Canada dealer’s licence and associated business related to Psilocybin, Psilocin, other psychedelic substances, some being synthetically formulated, and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 9, 2023, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.